Genetically engineered nanomodulators elicit potent immunity against cancer stem cells by checkpoint blockade and hypoxia relief

Yuanwei Pan, Ling Yu, Lujie Liu, Jing Zhang, Shuang Liang, Badri Parshad, Jialin Lai, Limin Ma, Zhaohui Wang, Lang RaoBioactive 2024 · DOI

TL;DR

This paper introduces a novel nanoplatform, hMnO₂@gCMs, designed to combat cancer stem cells (CSCs) by simultaneously addressing tumor hypoxia and blocking immune evasion pathways. By combining hollow manganese dioxide (hMnO₂) for oxygen generation and genetically engineered CSC membranes (gCMs) expressing SIRPα, these nanomodulators effectively target and eliminate CSCs, showing promising results in preclinical models.

What Problem Does This Paper Address?

Cancer stem cells (CSCs) are a critical challenge in cancer therapy due to their self-renewal capabilities, resistance to conventional treatments, and their role in tumor recurrence and metastasis. While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their efficacy against CSCs is often hampered by the hypoxic tumor microenvironment. Hypoxia not only promotes CSC survival and stemness but also upregulates CD47 on CSCs, a "don't eat me" signal that prevents immune cells, particularly macrophages, from engulfing and destroying them. This creates a significant barrier to effective immunotherapy for CSCs. The paper aims to overcome this by developing a therapeutic strategy that simultaneously alleviates hypoxia and blocks the CD47-SIRPα immune checkpoint.

Methods

The core innovation lies in the development of hollow manganese dioxide nanoparticles coated with genetically engineered cancer stem cell membranes (hMnO₂@gCMs).

  • hMnO₂ Core: Hollow manganese dioxide nanoparticles were synthesized. These nanoparticles are designed to decompose endogenous hydrogen peroxide (H₂O₂) within the tumor microenvironment, generating oxygen (O₂). This process effectively alleviates tumor hypoxia.
  • Genetically Engineered CSC Membranes (gCMs): Cancer stem cell membranes were harvested from B16F10 cells engineered to overexpress a SIRPα variant. These membranes were then coated onto the hMnO₂ nanoparticles. The gCMs serve two key functions:
  • Homologous Targeting: The CSC membranes provide a natural targeting mechanism, allowing the nanoparticles to preferentially accumulate at CSC-rich tumor sites.
  • Immune Checkpoint Blockade: The overexpressed SIRPα on the gCM shell acts as a decoy receptor, effectively blocking the CD47-SIRPα "don't eat me" pathway and promoting phagocytosis of CSCs by macrophages.
  • Synthesis and Characterization: The hMnO₂ nanoparticles were synthesized using a microemulsion method followed by etching to create the hollow structure. The gCMs were prepared from engineered CSCs. The hMnO₂@gCMs nanocomposites were then formed by coating the hMnO₂ core with the gCMs. Various characterization techniques, including TEM, XPS, DLS, and zeta potential measurements, were used to confirm the morphology, composition, and surface properties of the nanoparticles.
  • In Vitro and In Vivo Studies: The efficacy of hMnO₂@gCMs was evaluated through a series of in vitro assays (cell viability, cellular uptake, hypoxia relief, stemness gene expression, tumorsphere formation) and in vivo studies using a B16F10-CSC bearing melanoma mouse model. These studies assessed biocompatibility, tumor targeting, hypoxia alleviation, CSC marker expression, immune cell infiltration, and overall tumor growth inhibition.

Datasets

Not discussed in the paper. The study primarily relies on in vitro cell culture experiments and in vivo animal models.

Key Insights and Ideas

  • Synergistic Approach: The most significant insight is the successful combination of hypoxia relief and immune checkpoint blockade within a single nanoplatform. This dual action addresses two major hurdles in CSC immunotherapy.
  • Biomimicry for Targeting: Utilizing CSC membranes for coating the nanoparticles provides a highly specific and effective homologous targeting mechanism, ensuring the therapeutic agent reaches the intended CSCs.
  • Hypoxia as a Regulator of CD47: The study reinforces the understanding that tumor hypoxia directly drives CD47 overexpression in CSCs, highlighting hypoxia alleviation as a crucial upstream strategy to reduce immune evasion.
  • Engineered Membranes for Enhanced Immunity: Genetically engineering the CSC membranes to overexpress SIRPα not only aids in targeting but also directly contributes to blocking the CD47-SIRPα axis, amplifying the immune response.
  • Reprogramming the Tumor Microenvironment: The nanoplatform appears to shift the balance of tumor-associated macrophages (TAMs) from an immunosuppressive M2 phenotype towards an anti-tumorigenic M1 phenotype, further enhancing immune surveillance.

Key Results

  • Effective Hypoxia Relief: hMnO₂@gCMs significantly reduced HIF-1α expression in both in vitro and in vivo models, indicating successful alleviation of tumor hypoxia.
  • Reduced CSC Markers: Treatment with hMnO₂@gCMs led to a significant decrease in CSC markers like CD133, Nanog, and Sox2, both in vitro and in vivo, demonstrating effective CSC elimination.
  • Enhanced Immune Cell Infiltration: The nanoplatform promoted the infiltration of M1 macrophages and CD8+ T cells into the tumor microenvironment, crucial for mounting an anti-tumor immune response.
  • Tumor Growth Inhibition: In the B16F10-CSC bearing melanoma mouse model, hMnO₂@gCMs treatment resulted in significantly suppressed tumor growth compared to individual components or saline control.
  • Biocompatibility: In vitro cytotoxicity assays and in vivo histological examination of major organs showed favorable biocompatibility of the hMnO₂@gCMs nanoparticles.

Limitations and Future Work

  • Preclinical Model: The study was conducted in a B16F10-CSC bearing melanoma mouse model. While promising, further validation in other cancer types and more complex in vivo models would be beneficial.
  • Long-Term Efficacy and Toxicity: While short-term biocompatibility was demonstrated, long-term effects and potential cumulative toxicity of the hMnO₂ component would require further investigation for clinical translation.
  • Combination Therapy Potential: The paper briefly mentions the potential for combining hMnO₂@gCMs with chemotherapy (e.g., DOX), suggesting future work could explore synergistic chemo-immunotherapy strategies.
  • Translational Challenges: Scaling up the production of genetically engineered membranes and ensuring consistent nanoparticle quality for clinical applications are significant future challenges.

Summary updated

Abstract

Rapid development of checkpoint inhibitors has provided significant breakthroughs for cancer stem cell (CSC) therapy, while the therapeutic efficacy is restricted by hypoxia-mediated tumor immune evasion, especially hypoxia-induced CD47 overexpression in CSCs. Herein, we developed a genetically engineered CSC membrane-coated hollow manganese dioxide (hMnO<sub>2</sub>@gCMs) to elicit robust antitumor immunity by blocking CD47 and alleviating hypoxia to ultimately achieve the eradication of CSCs. The hMnO<sub>2</sub> core effectively alleviated tumor hypoxia by inducing decomposition of tumor endogenous H<sub>2</sub>O<sub>2</sub>, thus suppressing the CSCs and reducing the expression of CD47. Cooperating with hypoxia relief-induced downregulation of CD47, the overexpressed SIRPα on gCM shell efficiently blocked the CD47-SIRPα "don't eat me" pathway, synergistically eliciting robust antitumor-mediated immune responses. In a B16F10-CSC bearing melanoma mouse model, the hMnO<sub>2</sub>@gCMs showed an enhanced therapeutic effect in eradicating CSCs and inhibiting tumor growth. Our work presents a simple, safe, and robust platform for CSC eradication and cancer immunotherapy.
BibTeX
@inproceedings{pan2024genetically,
  author = {Yuanwei Pan and Ling Yu and Lujie Liu and Jing Zhang and Shuang Liang and Badri Parshad and Jialin Lai and Limin Ma and Zhaohui Wang and Lang Rao},
  title = {{Genetically engineered nanomodulators elicit potent immunity against cancer stem cells by checkpoint blockade and hypoxia relief}},
  booktitle = {Bioactive},
  year = {2024},
  doi = {10.1016/j.bioactmat.2024.04.008},
}
Figure